Levi’s boosts its sales outlook for first half of 2021 on vaccine hopes
Category: #tech  By Nikita Chaurasia  Date: 2021-04-10
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Levi’s boosts its sales outlook for first half of 2021 on vaccine hopes

Levi Strauss & Co., an American clothing company, has reportedly raised its half-yearly revenue growth projection, counting on COVID-19 vaccine rollouts to reinstate the popularity of its physical stores. The denim-maker had previously beaten estimates for quarterly sales on a pandemic-induced e-commerce boost.

The company’s shares rose by 5% in extended trading, as it also raised its estimated quarterly dividend from 4 cents per share to 6 cents.

Many clothing and apparel companies, including Kohl’s Corp., and Nike Inc. have also kept a positive outlook on market growth, and expect store traffic to rebound to normal levels soon, despite the pandemic-led boom in online sales.

Chief Executive Officer of Levi Chip Bergh was quoted saying that the progress of vaccine rollouts will bring about consumer demands for more brick-and-mortar stores. He also added that the pandemic has only served to make Levi a stronger business than it was one year ago. 

The jeans-maker said that over 40% of its stores in Europe have been shut down, and the rest are operating on reduced hours on account of lockdown restrictions.

Levi reported its expected revenue to increase by 24-25%, up from the previous range of 18-20%, during the first half of 2021. The company is also expected to adjust its profit per share for the period at around 41-42 cents, while analysts estimate the average profit per share of 30 cents for the first two quarters.

Net revenue dropped by 13% to USD 1.31 billion during the quarter ended Feb. 28, 2021, but the figures were above analysts’ expectations of USD 1.25 billion.

Levi’s online revenue, which includes apparel sales from wholesale partners, rose by 41% and covered the company’s drop in physical store sales. On an adjusted basis, Levi’s EPS stood at 34 cents per share, 9 cents above analyst estimates of 25 cents per share.

Source Credit –

https://www.reuters.com/article/us-levi-strauss-results/levi-strauss-raises-sales-outlook-on-vaccine-hopes-shares-jump-idUSKBN2BV2X4

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Moderna failed to meet FDA’s requirements for COVID-19 booster vaccines

Moderna failed to meet FDA’s requirements for COVID-19 booster vaccines

By Nikita Chaurasia

Scientists from the U.S. Food and Drug Administration (FDA) claimed that Moderna did not meet all the requirements to support the use of COVID-19 booster shots. This is because the first two shots already showed a strong efficacy rate. Documents rel...

Canada’s healthcare sector likely to brace for looming staff shortages

Canada’s healthcare sector likely to brace for looming staff shortages

By Nikita Chaurasia

According to reliable sources, Canada’s overworked healthcare sector is now bracing for upcoming staff shortages and potential layoffs, as the country accelerates its vaccination drive before the deadline. The development comes at a time when l...

Rocket Lab, Kineis sign multi-launch contract for IoT constellation

Rocket Lab, Kineis sign multi-launch contract for IoT constellation

By Nikita Chaurasia

The space industry is booming as new companies with fresh ideas for space-based applications take advantage of declining launch and satellite costs. Out of those firms, Rocket Lab USA bagged a contract to launch 25 satellites on five missions exclusi...